In a 12-month randomised controlled trial of 297 adults with metabolic dysfunction-associated steatotic liver disease (MASLD), all three intervention arms — minimal intervention therapy (MIT), structured dietitian-led lifestyle coaching, and mobile health (m-health) — reduced liver steatosis by a clinically meaningful and statistically equivalent ~22–24 dB/m on controlled-attenuation parameter (CAP) scoring. Only the m-health arm produced a significant reduction in serum AST (−2.81 U/L), a steatohepatitis marker, though this effect was modest. Critically, no intervention moved the needle on liver fibrosis, the stage most predictive of long-term mortality.
Fatty liver disease now affects roughly one in four adults globally and sits upstream of cirrhosis, hepatocellular carcinoma, and cardiovascular mortality — yet no approved pharmacotherapy existed until very recently. The striking parity between arms is the headline finding: even low-intensity minimal intervention drove ~24 dB/m CAP reduction, suggesting that structured contact itself, rather than the mode of delivery, may be the active ingredient. For health systems, this matters enormously — scalable app-based approaches could democratise care without sacrificing efficacy. However, limitations temper enthusiasm: this is a single-centre Belgian trial, fibrosis (the hard endpoint) was unmoved, and 12 months may be too short to detect structural liver change. The finding is confirmatory of m-health feasibility but stops short of paradigm-shifting — multi-centre replication with longer follow-up and hard clinical endpoints is essential before wholesale adoption.